Hutchison China MediTech Limited, also known as Chi-Med, has put its radiation sensitizer, HMPL-002, on clinical hold because the drug did not provide a clear clinical advantage. The data came from a Phase II proof-of-concept trial, conducted in China, in patients with stage III non-small cell lung cancer. HMPL-002 was administered in addition to standard chemo-radiotherapy and compared to the standard treatment. More details...

Stock Symbol: (AIM: HCM)